Ubiquigent Restricted (Dundee, Scotland), a drug discovery and growth firm harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of excessive unmet medical want, at present introduced the appointment of Dr Xavier Jacq to its Scientific Advisory Board (SAB). The SAB is chaired by Professor Sir Philip Cohen. Following the current appointments of Professor’s Helen Walden and John Davis, the addition of Xavier additional strengthens Ubiquigent’s DUB-associated experience and can assist drive the continued development of the Firm within the DUB drug discovery area.
Xavier co-founded Mission Therapeutics (Mission), the place he held the positions of VP Scientific Affairs and Director of Biology. On this function, he targeted on researching and exploiting the ubiquitin proteasome system (UPS) and was a key driver behind Mission’s DUB-focused technique. Xavier then moved to Almac Discovery as VP of Biology, reinforcing his experience within the DUB area, adopted by Dunad Therapeutics, a developer of focused protein degradation-based therapies, as Senior Vice President. Xavier is at present Chief Scientific Officer at moa Expertise, an Oxford-based firm investigating nature’s design for novel herbicide modes of motion. With over 22 years’ business expertise, Xavier has established a confirmed monitor document in early-stage discovery and growth that spans oncology, metabolism, immunology and CNS therapeutics. He holds a PhD in Biochemistry from Louis Pasteur College in Strasbourg, France and accomplished his postdoctoral coaching in Most cancers Biology at Colombia College, NYC, USA.
Dr Xavier Jacq, SAB Member, Ubiquigent, stated: “There’s a rising recognition for the function of DUBs in lots of disease-relevant pathways, making the UPS some of the promising sources of druggable targets for novel therapeutics. Ubiquigent’s complete method to DUB drug discovery is exclusive, and I sit up for working with the staff to advance each inside and partnership-based drug discovery programmes.’
Jason Mundin, Chief Govt Officer, Ubiquigent commented: “We’re delighted to have Xavier be a part of our SAB, the most recent in a sequence of appointments to additional strengthen our place as consultants within the DUB area. His intensive analysis and business expertise targeted on the UPS and the DUBs will likely be invaluable in creating our portfolio of novel DUB modulators and related drug discovery programmes.”
To seek out out extra concerning the Firm’s SAB, please go to https://www.ubiquigent.com/about-us.
Ubiquigent will likely be in San Francisco for JPM Week 2023, 9–12 January. Schedule a one-to-one assembly by the BIO Partnering or the Biotech Showcase platforms to study extra concerning the Firm’s DUB-focused drug discovery pipeline and partnering alternatives.
The put up Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board appeared first on BioTechniques.
